Suppr超能文献

瑞典促甲状腺激素(TSH)分泌型垂体腺瘤的发病率和患病率。

National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden.

机构信息

Sahlgrenska Academy, University of Gothenburg, SE-405 30 Göteborg, Sweden.

出版信息

J Clin Endocrinol Metab. 2013 Feb;98(2):626-35. doi: 10.1210/jc.2012-3362. Epub 2013 Jan 7.

Abstract

CONTEXT

TSH-secreting pituitary adenomas (TSHomas) are rare. Epidemiological data are scant and there are no reports on national incidence.

OBJECTIVE

The objective of the study was to estimate the national Swedish incidence and prevalence of TSHomas.

DESIGN

This was an observational study.

SETTING

The study was conducted at tertiary referral centers.

PATIENTS

The Swedish Pituitary Registry and World Health Organization International Statistical Classification of Diseases and Related Health Problems coding at all university hospitals were used to identify patients diagnosed with TSHomas 1990-2010. The identified patients' medical records were studied until the latest follow-up [median 5.0 years (range < 1-20 years)].

MAIN OUTCOME MEASUREMENTS

Incidence, prevalence, demographics, tumor characteristics, treatment outcome, and thyroid hormone level at diagnosis were measured.

RESULTS

The age-standardized national incidence of 28 TSHoma patients was 0.15 per 1 million inhabitants per year, with an increasing incidence over time (0.05 per 1 million per year in 1990-1994 to 0.26 per 1 million per year in 2005-2009). The national prevalence in 2010 was 2.8 per 1 million inhabitants, in which 0.85 per 1 million had active disease. Most patients (n = 22) underwent pituitary surgery, 5 had radiotherapy, and 6 had somatostatin analogues. Eighteen patients were considered cured at the latest follow-up; 25% remained uncontrolled. Subjects treated for putative primary hyperthyroidism prior to diagnosis had TSH levels more than double those with intact thyroid at diagnosis (P = .013). The median time to diagnosis was longer for women than men (4 vs < 1 year, P = .026). More women than men were treated surgically (94.1% vs 54.5%, P = .022).

CONCLUSION

This is the first estimate of a national incidence of TSHoma. Additional epidemiological studies are needed to compare these results with other geographical areas. This study suggests an increased incidence of TSHomas, in agreement with reports on other pituitary adenomas.

摘要

背景

促甲状腺激素(TSH)分泌性垂体腺瘤(TSHoma)较为罕见。目前仅有少量流行病学数据,且未见全国发病率的报道。

目的

本研究旨在评估瑞典全国 TSHoma 的发病率和患病率。

设计

本研究为观察性研究。

地点

在三级转诊中心开展。

患者

利用瑞典垂体瘤登记处和世界卫生组织国际疾病分类和相关健康问题编码,在所有大学附属医院识别 1990 年至 2010 年间诊断为 TSHoma 的患者。对识别出的患者病历进行研究,随访时间截止至最近(中位时间为 5.0 年[范围为<1-20 年])。

主要观察指标

发病率、患病率、人口统计学特征、肿瘤特征、治疗结局以及诊断时的甲状腺激素水平。

结果

28 例 TSHoma 患者的年龄标准化全国发病率为 0.15/100 万居民·年,发病率随时间呈上升趋势(1990-1994 年为 0.05/100 万·年,2005-2009 年为 0.26/100 万·年)。2010 年全国患病率为 2.8/100 万,其中 0.85/100 万处于活动状态。大多数患者(n=22)接受了垂体手术,5 例接受了放疗,6 例接受了生长抑素类似物治疗。18 例患者在最近的随访中被认为已治愈;25%的患者仍未得到控制。与诊断时甲状腺功能正常的患者相比,诊断前有疑似原发性甲状腺功能亢进症治疗史的患者 TSH 水平高出两倍以上(P=0.013)。女性的诊断中位时间长于男性(4 年比<1 年,P=0.026)。接受手术治疗的女性多于男性(94.1%比 54.5%,P=0.022)。

结论

这是 TSHoma 全国发病率的首次评估。需要开展更多的流行病学研究来比较这些结果与其他地理区域的差异。本研究提示 TSHoma 的发病率增加,这与其他垂体腺瘤的报道一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验